Cantargia’s CAN10 Antibody Shows Promise in Inhibiting Vascular Inflammation

Cantargia AB ( (SE:CANTA) ) has provided an update.

Cantargia has published promising preclinical results demonstrating the potential of their CAN10 antibody to inhibit vascular inflammation by targeting IL1RAP. These findings indicate that IL1RAP-targeted therapy could be a novel strategy to mitigate vascular inflammation, with potential implications for treating several inflammatory diseases, including cardiovascular diseases. The study, conducted in collaboration with Örebro University, highlights the antibody’s ability to block inflammatory markers and suggests a translational possibility into human cardiovascular diseases, potentially enhancing Cantargia’s positioning in the biotechnology industry.

More about Cantargia AB

Cantargia AB is a biotechnology company focused on developing antibody-based treatments for life-threatening diseases. The company has established a platform based on the protein IL1RAP, which is involved in various cancer forms and inflammatory diseases. Cantargia’s oncology program includes the antibody nadunolimab (CAN04), primarily studied in combination with chemotherapy for pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer. Their second development program, CAN10, targets serious autoimmune/inflammatory diseases, initially focusing on hidradenitis suppurativa and systemic sclerosis.

YTD Price Performance: -9.82%

Average Trading Volume: 905,081

Current Market Cap: SEK378.9M

For detailed information about CANTA stock, go to TipRanks’ Stock Analysis page.